Kimberley Delaunay
Paris, 75006, France
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 18 publications
LRP2 is a potential molecular target for nonsyndromic pathological myopia.
Journal: JCI insight
Published: March 04, 2025
Transferrin is a drug candidate for the treatment of dry age-related macular degeneration (AMD).
Journal: Cell death & disease
Published: January 17, 2025
Phototoxicity of low doses of light and influence of the spectral composition on human RPE cells.
Journal: Scientific reports
Published: November 07, 2023
Comparative Analysis of Urso- and Tauroursodeoxycholic Acid Neuroprotective Effects on Retinal Degeneration Models.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: January 31, 2022
Meteorin Is a Novel Therapeutic Target for Wet Age-Related Macular Degeneration.
Journal: Journal of clinical medicine
Published: June 01, 2021
Long-Term Oral Treatment with Non-Hypoglycemic Dose of Glibenclamide Reduces Diabetic Retinopathy Damage in the Goto-KakizakiRat Model.
Journal: Pharmaceutics
Published: May 31, 2021
Mineralocorticoid Receptor Pathway and Its Antagonism in a Model of Diabetic Retinopathy.
Journal: Diabetes
Published: February 03, 2021
Oral Ursodeoxycholic Acid Crosses the Blood Retinal Barrier in Patients with Retinal Detachment and Protects Against Retinal Degeneration in an Ex Vivo Model.
Journal: Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics
Published: January 13, 2021
Macular edema: Understand mechanisms to develop treatments
Journal: Medecine sciences : M/S
Published: August 22, 2020
The antidiabetic drug glibenclamide exerts direct retinal neuroprotection.
Journal: Translational research : the journal of laboratory and clinical medicine
Published: May 19, 2020
Last Updated: 09/26/2026